• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

New center promotes advocacy for gynecological cancer patients

by Marisa Wexler, MS | Nov 26, 2025 | Myeloma News

The Ovarian Cancer Research Alliance (OCRA) launched a project to push lawmakers to enact legislation that will improve the lives of people affected by ovarian cancer and other types of gynecological cancers. OCRA’s new Center for Public Policy is a dedicated arm of...

FDA clears Thermo Fisher EXTENT system for myeloma diagnosis

by Andrea Lobo | Nov 25, 2025 | Myeloma News

Thermo Fisher Scientific has received U.S. Food and Drug Administration (FDA) clearance for its EXENT System, an automated test that helps doctors diagnose multiple myeloma. The system detects and identifies abnormal antibodies called M-proteins, which are produced by...

Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma

by MM360 Staff | Nov 25, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial

by MM360 Staff | Nov 25, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

by MM360 Staff | Nov 25, 2025 | Uncategorized

Source: CURE articles Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis
  • (no title)
  • (no title)
  • (no title)
  • Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma
  • Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis
  • (no title)
  • Measurable residual disease assessment in multiple myeloma
  • Oncolytics to test immunotherapy against aggressive pancreatic cancer
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT